Sakura Bio is developing an off-the-shelf allogeneic T-cell therapy, Skill-T, which utilizes a proprietary manufacturing process to produce non-genetically modified T-cells with high anti-tumor cytotoxic activity and no toxicity to healthy tissue. This therapy aims to provide a safe and effective treatment option for patients with hematological malignancies and solid tumors, eliminating the risk of Graft-versus-host disease (GVHD) commonly associated with other T-cell therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Current T-cell therapies for cancer often involve complex and costly manufacturing processes, and may carry the risk of Graft-versus-host disease (GVHD). This limits accessibility and poses safety concerns for patients with hematological malignancies and solid tumors.
Solution
Sakura Bio is developing Skill-T, an off-the-shelf allogeneic T-cell therapy designed to overcome the limitations of existing T-cell treatments. Skill-T cells are non-genetically modified and produced through a proprietary, cost-effective manufacturing process. Preclinical studies have demonstrated Skill-T's potent anti-tumor cytotoxic activity against both hematological malignancies and solid tumors, without toxicity to healthy tissue or the risk of GVHD. The company has optimized a scaled-up manufacturing process and cryopreservation protocol to ensure high recovery and efficacy of the final product, and is progressing towards Phase I clinical trials.
Target Audience
The primary target audience includes patients with hematological malignancies and solid tumors who require safe, effective, and accessible T-cell therapy options.
Features
- Off-the-shelf, allogeneic T-cell therapy, eliminating the need for patient-specific cell engineering
- Non-genetically modified T-cells with a high safety profile and no risk of Graft-versus-host disease (GVHD)
- Proprietary manufacturing process that is simple and cost-effective
- Demonstrated in vitro and in vivo efficacy against hematological malignancies and solid tumors
- Scaled-up manufacturing process and efficient cryopreservation protocol for high recovery yield